Product Information
TRI-NYMYO 28 TABLET is a generic product labeled by Mayne Pharma, priced at $0.1373 per EA under NDC 51862064606. Its NADAC has been published 161 times since Oct 20, 2021.
Manufacturer
Mayne PharmaNDC
51862064606
Classification
Generic
Dosage Form
KIT
Last Updated
10/23/2024
Approval Type
Generic (ANDA)
FDA Application
ANDA090524On Market Since
10/24/2020
Price Statistics
The NADAC for TRI-NYMYO 28 TABLET has been published 161 times since Oct 20, 2021, and over the history we have for it it has declined 24.3%. The table below summarizes its recorded NADAC range and movement.
| Current price | $0.1373 per EA |
|---|---|
| All-time high | $0.1848 (Dec 15, 2021) |
| All-time low | $0.1072 (Jul 17, 2024) |
| Median price | $0.1418 |
| Average price | $0.1446 |
| Largest weekly change | -19.9% (Jul 17, 2024) |
| Weeks tracked | 161 |
| Tracking since | Oct 20, 2021 |
Generic Alternatives
The matcher finds 7 NADAC-published products sharing this drug's active ingredient, strength, and dosage form across 7 manufacturers (up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 24% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.
Frequently asked questions
What is the NADAC price of TRI-NYMYO 28 TABLET?
The current National Average Drug Acquisition Cost (NADAC) for TRI-NYMYO 28 TABLET, manufactured by Mayne Pharma, is $0.1373 per EA (NDC 51862064606), effective Nov 13, 2024.
How has the price of TRI-NYMYO 28 TABLET changed over time?
Over the history we have for it, the NADAC for TRI-NYMYO 28 TABLET has declined 24.3%. It has been tracked across 161 weekly CMS publications since Oct 20, 2021.
What are the highest and lowest recorded NADAC prices for TRI-NYMYO 28 TABLET?
Since Oct 20, 2021, the NADAC for TRI-NYMYO 28 TABLET has ranged from a low of $0.1072 (Jul 17, 2024) to a high of $0.1848 (Dec 15, 2021), with a median of $0.1418 per EA.
Are there cheaper alternatives to TRI-NYMYO 28 TABLET?
Yes. 7 NADAC-published products share the same active ingredient, strength, and dosage form. The lowest-priced option, TRI-VYLIBRA LO TABLET, is $0.1049 per EA — about 24% below TRI-NYMYO 28 TABLET.
Who manufactures TRI-NYMYO 28 TABLET?
TRI-NYMYO 28 TABLET (NDC 51862064606) is labeled by Mayne Pharma, and CMS classifies it as a generic product.
Related Drugs
Same classification